Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Exclusion Criteria

• •Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
• •Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
• •Has evidence of any leptomeningeal disease
• •Has clinically significant corneal disease
• •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
• •Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection